To validate the proteomics findings, we performed immunohistochemical staining on glioma Grade 2–4 tumors, which revealed that glioblastoma and TMZ-resistant recurrent tumors had the highest SRPX protein levels. Here, SRPX is linked to central nervous system cancer.